Early detection value of miR-29a in patients with acute myocardial infarction
By
Yanqing, Wang
Peng, Gao
Yawei, Duan
Hanqi, Su
Haibo, Wu
Yuan, Jia
Zhang, Yue
Jia, Liu
Hongxiao, Li
李, 向明
Wenjuan, Li
Xiaoshuai, Shi
Tingting, Liu
Teng, Huang
Rongpin, Du
March 23, 2026
Clinical Scorecard: Diagnostic Significance of miR-29a in Early Stages of Acute Myocardial Infarction
At a Glance
Category Detail
Condition Acute Myocardial Infarction (AMI) Key Mechanisms Myocardial remodeling and its early detection Target Population Patients with ST-elevation myocardial infarction (STEMI) Care Setting Prospective cohort study in a clinical setting
Key Highlights
Serum miR-29a levels significantly elevated in STEMI patients compared to controls Positive correlation with sST2, NT-proBNP, and Tei index Inverse correlation with left ventricular ejection fraction (LVEF) Combination of miR-29a with NT-proBNP and/or sST2 enhances diagnostic accuracy Highest AUC of 0.904 with 97.4% specificity and 76.9% sensitivity Guideline-Based Recommendations
Diagnosis
Utilize serum miR-29a as a biomarker for early detection of myocardial remodeling in AMI Management
Consider the triad of miR-29a, NT-proBNP, and sST2 for improved diagnostic accuracy Monitoring & Follow-up
Monitor serum miR-29a levels alongside traditional biomarkers in STEMI patients Risks
Inadequate early detection of myocardial remodeling may lead to heart failure Patient & Prescribing Data
52 patients with STEMI and 39 healthy controls
Primary percutaneous coronary intervention within 12 hours of symptom onset
Clinical Best Practices
Incorporate miR-29a testing in the diagnostic workup for AMI Use miR-29a in conjunction with established biomarkers for enhanced prognostic evaluation Related Resources & Content
